SGLT2 Inhibitors Show High Cardiovascular - and Renal- Protective Effects in T2D
Zhang X-L, Zhu Q-Q, Chen Y-H, et al. Cardiovascular safety, long‐term noncardiovascular safety, and efficacy of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta‐analysis with trial sequential analysis [published online January 20, 2018]. J Am Heart Assoc. doi:10.1161/JAHA.117.007165
Results of the meta-analysis showed that SGLT2 inhibitors significantly reduced the risks of major adverse cardiac events.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors showed high cardiovascular- and renal-protective effects as well as good long-term noncardiovascular safety with sustained efficacy in patients with…